Submit Deal

TENEOBIO

Summary

TeneoBio is an operator of a biotechnology company intended to develop biologics, human heavy-chain antibodies for the treatments of cancer, autoimmunity, and infectious diseases.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 650 M

Avg. Deal Size£ 650 M

Market Context

Senior Management

Stephen Dance
CFO
Omid Vafa
Chief Business Officer

Sort

27 Jul 2021|United States|Biotechnology

Target: TENEOBIO

Bidder: AMGEN INC

7 Service Providers

2 Target | 3 Bidder | 2 Vendor

43 Dealmakers

12 Target | 27 Bidder | 4 Vendor

£ 650 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy